Get the Stockscreener App
0.3599
1.12%
0.004
Biodesix Inc stock is traded at $0.3599, with a volume of 2.63M.
It is up +1.12% in the last 24 hours and down -27.32% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
See More
Previous Close:
$0.3559
Open:
$0.364
24h Volume:
2.63M
Relative Volume:
0.37
Market Cap:
$52.74M
Revenue:
$49.09M
Net Income/Loss:
$-52.15M
P/E Ratio:
-0.5537
EPS:
-0.65
Net Cash Flow:
$-45.93M
1W Performance:
+19.49%
1M Performance:
-27.32%
6M Performance:
-71.88%
1Y Performance:
-74.48%
1-Day Range:
$0.34
$0.3679
1-Week Range:
$0.2541
$0.5147
52-Week Range:
$0.1718
$2.04
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
0.3599 | 32.24M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
393.08 | 152.86B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
184.12 | 136.66B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
499.08 | 41.18B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
107.83 | 32.05B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
135.99 | 24.29B | 15.50B | 1.33B | 2.16B | 7.34 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting | BDSX Stock News - GuruFocus
Biodesix to Present New Data on Host Immune Classifier for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - GlobeNewswire
Game-Changing Cancer Test Triples Survival Rate: New Clinical Data Transforms Lung Cancer Treatment - Stock Titan
Biodesix (BDSX) Target Price Reduced to $2 by Scotiabank | BDSX Stock News - GuruFocus
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut By Stocktwits - Investing.com India
Scotiabank cuts Biodesix stock target to $2, maintains outlook By Investing.com - Investing.com Canada
Biodesix Approves Reverse Stock Split at Annual Meeting - TipRanks
Scotiabank cuts Biodesix stock target to $2, maintains outlook - Investing.com
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX S - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences | BDSX Stock News - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences - GlobeNewswire
Biodesix Executives Set for Major Investor Conferences: William Blair and Craig-Hallum Presentations Ahead - Stock Titan
Director’s Massive Stock Purchase Signals Confidence in Biodesix! - TipRanks
Biodesix's (BDSX) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Craig Hallum Cuts Biodesix (NASDAQ:BDSX) Price Target to $1.50 - Defense World
Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion - MSN
Susquehanna International Group LLP Grows Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Biodesix, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers - simplywall.st
Biodesix Announces New Clinical and Economic Data for Its Nodify Lung® Tests At ISPOR and ATS - marketscreener.com
News Flash: 6 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat - Yahoo Finance
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS | BDSX Stock News - GuruFocus
Biodesix, Inc. to Present New Data on Lung Cancer Diagnosis and Testing at ISPOR and ATS 2025 Conferences - Nasdaq
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS - GlobeNewswire
New Clinical Data: Biodesix Lung Cancer Tests Could Prevent 60% of Unnecessary Invasive Procedures - Stock Titan
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award - GlobeNewswire
Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Craig-Hallum Adjusts Price Target for Biodesix (BDSX) | BDSX Sto - GuruFocus
Diagnostic Leader Biodesix Clinches Elite Colorado Workplace Award, Employee Survey Reveals Why - Stock Titan
Biodesix stock plunges as life-sciences firm cuts sales projection - BizWest
Biodesix (BDSX): Analyst Maintains Buy Rating Despite Lowered Pr - GuruFocus
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BD - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating By Investing.com - Investing.com Nigeria
Biodesix stock target cut to $2 by TD Cowen, retains buy rating - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates - MSN
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BDSX Stock News - GuruFocus
Biodesix Inc Reports Q1 2025 Earnings: EPS of -$0.08 Misses Esti - GuruFocus
Biodesix stock rating cut to Market Perform at William Blair By Investing.com - Investing.com South Africa
BDSX: Canaccord Genuity Lowers Price Target for Biodesix | BDSX Stock News - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating - Investing.com Australia
BDSX Reports Q1 Revenue Below Expectations, Highlights Strategic - GuruFocus
Biodesix price target lowered to $1.50 from $2.50 at Canaccord - TipRanks
Biodesix (BDSX) Price Target Reduced as 2025 Revenue Outlook Dec - GuruFocus
Biodesix price target lowered to $1.50 from $3 at Craig-Hallum - TipRanks
Biodesix price target lowered to $2 from $3 at TD Cowen - TipRanks
Biodesix (BDSX) Downgraded to Market Perform by William Blair | - GuruFocus
Biodesix (BDSX) Target Price Reduced to $2 Amid Revenue Challeng - GuruFocus
Biodesix (BDSX) Price Target Reduced as 2025 Revenue Outlook Declines | BDSX Stock News - GuruFocus
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):